HDAC2 and PCNA expression is correlated to decreasing of endoxifen sensitivity in human breast cancer stem cells ALDH+ by Dewi, Syarifah et al.
Vol. 10, No. 2, December 2019 HDAC2 and PCNA expression correlated to endoxifen resistancy 77
HDAC2 and PCNA expression is correlated to decreasing of endoxifen 
sensitivity in human breast cancer stem cells ALDH+
DOI: dx.doi.org/10.22435/hsji.v10i2.2449
Syarifah Dewi1, Mohamad Sadikin1, Muchlis Ramli2, Septelia Inawati Wanandi1
1 Department of Biochemistry and Molecular Biology, Faculty of Medicine Universitas Indonesia
2 Department of Oncology Surgery, Faculty of Medicine Universitas Indonesia
Corresponding address: Septelia Inawati Wanandi 
Email: septelia.inawati@ui.ac.id
Received: October 10, 2019; Revised: November 7, 2019; Accepted: November 22, 2019
Abstrak
Latar belakang: Sel punca kanker payudara (breast cancer stem cells/BCSC) adalah subpopulasi sel 
kanker yang memiliki kemampuan menghasilkan tumor baru dan bersifat seperti sel punca. Penelitian 
kami sebelumnya menggunakan jaringan kanker payudara mengungkapkan bahwa ekspresi gen histone 
deacetylase 2 (HDAC2) dan proliferating cell nuclear antigen (PCNA) ditemukan perbedaan signifikan 
setelah terapi neoajuvan hormon dan kemoterapi. Penelitian ini bertujuan untuk menganalisis hubungan 
antara ekspresi HDAC2 dan PCNA dengan kelangsungan hidup sel punca kanker payudara dengan 
penanda aldehyde dehydrogenase + (ALDH+) yang diberi perlakuan endoksifen.
Metode: Sampel adalah BCSC primer manusia ALDH+ yang diberi perlakuan endoksifen 4 uM masing-
masing selama 2, 4, 6, 8, 10, 12, 14 hari. Viabilitas sel dilihat dengan menggunakan trypan blue dan 
ekspresi mRNA HDAC2 dan PCNA ditentukan menggunakan qRT-PCR.
Hasil: Viabilitas BCSCs ALDH + menurun setelah 2 sampai 4 hari pemberian endoksifen. Pada periode 
ini juga didapatkan ekspresi mRNA HDAC2 dan PCNA mengalami penurunan. Tetapi setelah pemberian 
endoksifen selama 8 hari, viabilitas BCSCs ALDH + mengalami peningkatan dan ditemukan peningkatan 
yang signifikan pada hari ke-14 pemberian endoksifen. Ekspresi mRNA HDAC2 dan PCNA juga menunjukkan 
peningkatan mulai pada hari ke-8 dan terus meningkat hingga hari ke-14 pemberian endoksifen. Penelitian 
ini menunjukkan pola yang sama antara ekspresi mRNA HDAC2 dan PCNA dan viabilitas sel.
Kesimpulan: Induksi endoksifen yang lama menurunkan sensitivitas efek endoksifen pada BCSC manusia 
dan ekspresi HDAC2 dan PCNA berkorelasi dengan viabilitas BCSC manusia setelah induksi endoksifen. 
(Health Science Journal of Indonesia 2019;10(2):77-81)
Kata kunci: sel punca kanker payudara, viabilitas sel, HDAC2, PCNA, endoksifen
Abstract
Background: Breast cancer stem cells (BCSCs) are subpopulation of cancer cells that has the ability to 
generate new tumor and similar properties to stem cell. Our previous study using breast cancer patients 
revealed that gene expression of histone deacetylase 2 (HDAC2) and proliferating cell nuclear antigen 
(PCNA) were significantly altered after neoadjuvant hormone and chemotherapy. This study aimed to 
analyze the correlation between HDAC2 and PCNA expressions with the viability of breast cancer stem 
cells aldehyde dehydrogenase + (BCSC ALDH+) treated by endoxifen.
Method:  Samples are human primary BCSCs ALDH+ that treated with 4 uM of endoxifen for 2, 4, 6, 
8, 10, 12, 14 days, respectively. Cell viability was measured using trypan blue exclusion assay and the 
mRNA expressions of HDAC2 and PCNA were determined using qRT-PCR.
Results: The viability of BCSCs ALDH+ was decreased after 2 days until 4 days-endoxifen treatment. It also 
demonstrated that mRNA expression of HDAC2 and PCNA were decreased in this period. But after 8 days-
endoxifen treatment, the viability of BCSCs ALDH+ was increased. The increasing of viability was higher in 14 
days-endoxifen treatment. The mRNA expression of HDAC2 and PCNA also showed increasing begin on 8 days 
and continued to increase until 14-days endoxifen treatment. We found a similar pattern between HDAC2 and 
PCNA expression and cell viability
Conclusion: Prolonge endoxifen treatment decrease sensitivity of endoxifen effect in human BCSC and 
the expression of HDAC2 and PCNA are correlated to human BCSCs viability after endoxifen treatment. 
(Health Science Journal of Indonesia 2019;10(2):77-81)
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Epigenetic modifications play an important role in 
regulating biological processes. Histone deacetylation 
is one of epigenetic modifications that regulated by an 
enzyme family of histone deacetylases (HDACs). This 
enzyme will remove acetyl group from histones and 
resulting in a non-permissive chromatin conformation 
that suppress some genes transcription activities. Cancer 
is one of the diseases that could be affected by epigenetic 
alteration. Some studies reported that an increase in 
histone deacetylation causes increased cell proliferation, 
cell migration, angiogenesis and invasion by reducing 
transcription of tumor suppressor genes.1,2
Proliferating cell nuclear antigen (PCNA) is known 
as a molecular marker for proliferation because 
of its role in DNA replication. This protein is 
found overexpressed in cancer cells that have high 
proliferation.3 PCNA has proven correlated to worse 
disease progression and prognosis in cancer.
Approximately 70-80% of breast cancer has 
overexpression of estrogen receptor (ER). Breast 
cancer with hormone receptor (ER) positive has a good 
response to anti-estrogen or aromatase inhibitor as first 
line drug. Endoxifen is one of hydroxylated tamoxifen 
metabolit (4-hydroxy-N-desmethyl-tamoxifen) and 
significantly more potent than tamoxifen in its ability 
to bind to ER, and in suppression of ER-dependent 
breast cancer proliferation.5 
Breast cancer is a heterogenous disease which 
consists of  various type of cells including cancer 
stem cells. Breast cancer stem cells are known as a 
minor population among breast cancer cells that have 
capability to self renew, promote tumor growth and 
differentiate into all cell types in a tumor.6 Our recent 
study investigated gene expression profiles of stem 
cell and p53 in advanced breast cancer using next 
generation sequencing has reported that expression 
HDAC2 and PCNA is significantly altered after 
neoadjuvant hormone and chemotherapy.7,8 This study 
aims to investigate the mRNA expression of HDAC2 
and PCNA in human BCSC ALDH+ during endoxifen 
treatment and its correlation to cell viability.
METHODS
Samples are primary culture of human BCSCs 
ALDH+ which obtained from previous study that 
has isolated the cancer stem cells by ALDH1 marker 
(flowcytometer). The cells were grown in serum free 
medium DMEM F12 with 1% penicillin/streptomycin 
and 1% amphotericin B and incubated in 5% CO2 at 37˚C.
Cytotoxic Assay
Approximately 103 cells/well (96-microwell-plate) 
of human BCSCs ALDH+ were incubated in DMEM 
F12 with 5% CO2 at 37˚C and after 24 hours, the 
medium was replaced with 100 µL of fresh medium 
for control and fresh medium containing various 
concentration of endoxifen (0.1, 0.5, 1, 5, 10 and 20 
µM) for treatment group. Endoxifen-treated cells 
were incubated in 24 hours and the relative viable 
cells number was determined by MTS assay method 
(Promega®). After 24 hours, the medium culture 
was replaced with 120 μL fresh medium containing 
MTS:PMS ratio=20:1 and incubated in 1-4 hours. 
After the brown colour appears, the absorbance was 
read at 490 nm using microplate reader (Varioskan®). 
The 50% cytotoxic concentration (CC50) was 
determined from the dose-response curve. We 
determined the endoxifen concentration for the cells 
treatment not higher than CC50 concentration.   
Endoxifen treatment
Approximately 105 human BCSCs ALDH+ were 
plated each well in 12 well-plate and incubated 
overnight. Medium was replaced by endoxifen-
treated medium 4 µM (according to cytotoxic 
assay result) for treatment group and only complete 
medium DMEM F12 for the control group. Treatment 
was conducted during 2nd, 4th, 6 th, 8th, 10th, 12 th 
and 14th day and every 2 days the medium was 
refreshed and the cell number was counted both in 
endoxifen-treated and control group to determine the 
cell viability using trypan blue exclusion method. We 
collected the cells and isolated the total RNA using 
Tripure isolation reagent kit (Roche®) according to 
the manufacturer’s instructions.
Quantitative RT-PCR
The concentration of RNA was measured using 
spectrofluorometer (Varioskan, Thermo Scientific). 
One-step RT-PCR was carried out using ECO48® 
real time qPCR system (PCRmax). The RT PCR was 
performed in 20 µL volume with a 45˚C incubation for 
5 minutes initially, followed by a 3-minute incubation 
at 95˚C, then 40 cycles of 95˚C for 5 seconds, 60˚C for 
30 seconds, 72˚C for 30 seconds, and  melting curve 
incubation. We used 18sRNA as housekeeping gene. 
The primer sequences for quantitative RT-PCR are 
shown in table 1. The relative expression is produced 
by comparing Ct value of treatment group to control 
group and it is calculated by Livak formula.9
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Table 1. Primer sequences for HDAC2, PCNA and 18sRNA
No. Gene Primer Sequence Product
1. HDAC2 F: 5’- CCA TAA AGC CAC 
TGC CGA AG -3’
R: 5’- CAC AGC TCC AGC 
AAC TGA AC -3’
199 bp
2. PCNA F: 5’- CTT CCC TTA CGC 
AAG TCT CAG -3’
R: 5’- TTG AGT GCC TCC 
AAC ACC TT -3’
189 bp
3. 18sRNA F: 5’- AAA CGG CTA CCA 
CAT CCA AG -3’
R: 5’- CCT CCA ATG GAT 
CCT CGT TA -3’
155 bp
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RESULTS 
Cytotoxic Assay Analysis 
The cytotoxicity of endoxifen on primary human breast 
cancer stem cells (ALDH+) was determined by calculation 
of CC50 using several endoxifen concentrations (0.01, 
0.05, 0.1, 0.5, 1, 5, 10 and 20 μM).  The curve of CC50 for 
endoxifen was created based on endoxifen concentration 
againts the absorbance in log10 (figure 1). We got the 
CC50 of endoxifen on human breast cancer stem cells 
ALDH+ is 6 μM. Based on the cytotoxic assay result 
and optimization trial, we determined the endoxifen 
concentration is 4 µM for BCSC induction.  
Cell Viability
The number of cell viability was shown as the ratio 
(%) of live cell number in endoxifen group devided 
by live cell number in control group. Cell viability 
in endoxifen group appears to decrease in 2nd-day 
(51%) and  persistant until 6th-day (58%), but the 
cell viability found significantly increased after 8th-
day (82%) and more increased until 14th-day (99%) 
compare to control group (figure 2).
The mRNA expression of HDAC2 after endoxifen 
treatment
HDAC2 expression was decreased after 2 day-
treatment of endoxifen (0.790) compare to control 
group and it still decreased in 6 day-treatment (0.502). 
The expression was significantly increased in 10 and 
14 day-treatment (1.429 and 2.633) compare to 2 
day-treatment groups (figure 3). 
Figure 1. Cytotoxic concentration 50 of endoxifen treatment 
in human BCSC ALDH+. It shows the CC50 of en-
doxifen is 6 μM.
Figure 2. Cell viability of human BCSC ALDH+ treated by en-
doxifen 4 μM. Cell viability is rasio (%) of live cells 
in endoxifen treatment group compare to live cells in 
control group during 14 days treatment. Significancy 
compared to 2-day group (*p<0.05 and **p<0.001).
Figure 3. The mRNA relative expression of HDAC2 in hu-
man BCSC ALDH+ during 14 days treatment of 
endoxifen 4 μM. Significancy compared to 2-day 
treatment (E2) group  (*p<0.05).
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The mRNA expression of PCNA after endoxifen treatment
PCNA expression also decreased after 2 day-
treatment of endoxifen (0.767) compare to control 
group and it still decreased in 6 day-treatment (0.447). 
The expression was significantly increased in 10 and 
14 day-treatment (1.777 and 3.843) compare to 2 
day-treatment groups (figure 4).
DISCUSSION 
According to the cytotoxic assay result, we got the 
CC50 of endoxifen on human breast cancer stem cells 
ALDH+ is 6 μM. We also performed the optimization 
trial with several concentrations that lower than 
CC50. We determined the endoxifen concentration 
to BCSC treatment is 4 μM, because among the 
below CC50 concentration, this concentration gave 
the best inhibition towards BCSC proliferation.  
In this study, we demonstrated that the cell viability of 
human BCSCs was decreased after endoxifen treatment 
in the early period (2-day until 6-day treatment) 
however it would increase in late period (8-day until 
14-day treatment). The mRNA expression of HDAC2 
and PCNA also have the same pattern as cell viability 
after endoxifen treatment. It was decreased in the early 
period (2-day until 6-day treatment), but the expression 
would increase after 8-day until 14-day treatment. It 
showed us that the expression of HDAC2 and PCNA 
contributed to the human BCSCs cell viability.
Breast cancers are comprised of a highly 
heterogeneous population of cells, including the 
small population possess the ability to regenerate 
tumors in vivo. Another study was proved that histone 
deacetylases (HDACs) play essential roles in the 
cancer stem cells phenotype.10 Histon deacetylation is 
one of genetic modification that regulated by HDACs. 
Histone deacetylases (HDACs) regulate the expression 
and activity of numerous proteins involved in cancer 
initiation and cancer progression. By removal of acetyl 
groups from histones, HDACs create a non-permissive 
chromatin conformation that prevents the transcription 
of genes that encode proteins involved in tumorigenesis. 
In addition to histones, HDACs also deacetylate a 
variety of other protein targets including transcription 
factors and other abundant cellular proteins involved in 
control of cell growth, differentiation and apoptosis.11 
There are eighteen isoenzymes of HDACs that have 
already known but only class 1 HDAC (HDAC 1, 2, 3 
and 8) that reported involved in cancer.12
Endoxifen was proved to have better antiestrogen 
capacity compare to tamoxifen through ERα 
degradation and blocking ER activity.5 Some 
evidence suggests that ERα signaling has the 
potential to contribute to epigenetic alteration. 
Estrogen stimulation is shown to induce several 
histone modifications at the ERα target gene 
promoters such as acetylation, phosphorylation 
and methylation through interaction with histone 
modifying enzymes.13 One mechanism of drug 
resistance is overexpression of efflux transporters 
such as ATP binding casette subfamily B member 
1/ABCB1 (P-glycoprotein), where its expression is 
also found high in breast cancer stem cells.14 
Proliferating cell nuclear antigen (PCNA) is a 
cofactor of DNA polymerases that coordinate 
several functions in the replication process. Some 
studies reported that HDAC1 interacts with PCNA 
and HDAC1 and 2 are associated with newly 
replicated DNA.15 Another study demonstrated that 
HDAC inhibitors inhibit cell cycle progression and 
kill cancer cells by triggering DNA damage during 
DNA replication.16   
The increasing of cell viability after endoxifen 
treatment showed that the sensitivity of this 
treatment was decreased. It is showed by the 
viability in 8-day treatment was begin increased 
(figure 2). The decreasing of sensitivity treatment is 
early mechanism of drug resistance. In this study has 
revealed the high expression of HDAC2 and PCNA 
is associated with decreasing of endoxifen effect. 
It showed by the expression of HDAC2 and PCNA 
were begin increased in 8-day until 14-day treatment 
Figure 4. The mRNA relative expression of PCNA in human 
BCSC ALDH+ during 14 days treatment of endox-
ifen 4 μM. Significancy compared to 2-day treat-
ment (E2) group (*p<0.05 and **p<0.001).
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(figure 3 and 4). Other study reported that HDAC2 
overexpression correlated with the metastasis, 
progression and the increased Ki67, multidrug 
resistance protein expression in breast cancer.17 
HDAC2 will remove acetyl groups from histones 
and creates a closed chromatin structure that prevents 
the transcription of genes involved in growth arrest, 
differentiation, and apoptosis.11 The expression of 
PCNA is correlated with high cytological grading 
and poor prognosis in renal carcinoma.18 PCNA 
enhances the processivity of DNA polymerase  
which conducted DNA replication. Beside DNA 
synthesis, DNA polymerase  is involved in DNA 
damage revision, so it will increase the ability of 
cancer cells to avoid apoptosis.19
 
In conclusion, prolonged endoxifen therapy can 
cause decreasing in endoxifen effect which can lead 
to resistance. The increasing of HDAC2 and PCNA 
expressions correlated to the decreasing of endoxifen 
effect in human BCSC that showed by the increase 
of cell viability in late group of endoxifen treatment.
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